Drug
Quisinostat clinical trials
Also written JNJ-26481585.
Keep track of what changes. Save the quisinostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
NewVac LLC (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Nader Sanai (1) · Janssen Research & Development, LLC (1) · University of Miami (1)
Often tested with
Tested in the same studies.
Paclitaxel (2) · Carboplatin (2) · Gemcitabine (1) · Cisplatin (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses quisinostat is read from its arms, and is right about nine times in ten.
Testing it · 7
- Adjuvant Quisinostat in High-Risk Uveal MelanomaRecruitingPhase 2University of MiamiNCT06932757Written as Quisinostat
- Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype GlioblastomasActive, not recruitingEarly Phase 1Nader SanaiNCT06824662Written as Quisinostat
- Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With ChemotherapyCompletedPhase 2NewVac LLCNCT02948075Written as Quisinostat
- A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell LymphomaCompletedPhase 2Janssen Research & Development, LLCNCT01486277Written as Quisinostat, 12 mg
- Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With ChemotherapyCompletedPhase 1NewVac LLCNCT02728492Written as Quisinostat
- A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.CompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00677105Written as JNJ-26481585
- A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic SyndromeTerminatedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00676728Written as JNJ-26481585
Codes
What other systems call quisinostat · ClinicalTrials.gg INT005454
- MeSH (NLM) C541788quisinostatOne source ClinicalTrials.gov
- UNII (FDA) 9BJ85K1J8SQUISINOSTATConfirmed FDA, Wikidata
- Wikidata Q7272620quisinostatConfirmed FDA, Wikidata
- NCI Thesaurus C77912QuisinostatOne source FDA
- DrugBank DB12985One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C541788 | quisinostat | One source ClinicalTrials.gov |
| UNII (FDA) | 9BJ85K1J8S | QUISINOSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q7272620 | quisinostat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C77912 | Quisinostat | One source FDA |
| DrugBank | DB12985 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.